bullish
Icure Pharm (175250 KS): High Hope for Transdermal Patch-Type Dementia Treatment Option
446 Views20 Nov 2021 23:53
SUMMARY
- Icure Pharm Inc (175250 KS) obtained marketing approval for world’s first donepezil patch, a treatment of Alzheimer’s-type dementia in Korea. Donepezil accounts for 80% of the local Alzheimer's treatment market.
- For the domestic market, donepezil is expected to generate revenue of KRW 3.4 billion, equivalent to nearly 10% of existing annual revenue, with significantly higher profitability.
- The company is currently negotiating for sales right contract in the U.S. and aims to launch the product by 2024 in the U.S.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
- Icure Pharm (175250 KS): High Hope for Transdermal Patch-Type Dementia Treatment Option20 Nov 2021
- Icure Pharm IPO Summary - Front Runner of Dementia Patch Development Race02 Jun 2018
x